ANDREW GORDON SWICK, Ph.D. University of North Carolina Research Institute Kannapolis, NC 28081 704-250-5015 [email protected]

EDUCATION and TRAINING Certificate in Plant-Based Nutrition 2010 Cornell University online Ph.D. Nutritional Sciences 1987 University of Wisconsin-Madison M.S. Nutrition, 1982 University of Nebraska-Lincoln B.S. Animal Science 1981 University of Florida-Gainesville

Ph.D. Disseration: Activation of Brown Adipose Tissue Mitochodrial GDP Binding Sites. 201 pages; AAT 8716545.

M.S. Thesis: Effects of Bran Fiber on Serum of Subjects Fed Omnivore, Lacto-Ovo and Vegetarian Diets.

Fellowships: Postdoctoral Fellow 1990-1992 Johns Hopkins University Medical Center Postdoctoral Fellow 1987-1990 University of North Carolina-Chapel Hill

PROFESSIONAL EXPERIENCE Associate Professor 2010- present Department of Nutrition in the Schools of Public Health and Medicine at the University of North Carolina at Chapel Hill and the Nutrition Research Institute at the North Carolina Research Campus in Kannapolis, North Carolina.

Director of Obesity and Eating Disorders Research 2010- present University of North Carolina at Chapel Hill-Nutrition Research Institute at the North Carolina Research Campus in Kannapolis, North Carolina.

Senior Consultant 2009-present CSO and Senior Consultant at Illuminate BioPharma Consulting LLC. Provide expert advice to Biotechnology, Pharmaceutical and Venture Capital companies and non-profit organizations on drug discovery research and development in addition to obesity, nutrition and metabolic diseases.

Senior Director 2006-2009 Obesity and Atherosclerosis Translational Pharmacology in the Department of Cardiovascular and Metabolic and Endocrine Diseases (CVMED) at Pfizer Global Research and Development in Groton, Connecticut. Responsibilities included portfolio strategy and scientific leadership with respect to the identification and validation of therapeutic targets through nomination of compounds for development, target-specific and general biomarkers and translational pharmacology. Andrew Gordon Swick

 Directed efforts of the Obesity and Atherosclerosis teams (~50 Biologists).  Integral member and sole research representative on the Development Team for Obesity that is responsible for strategy and planning up to Phase 3.  Responsibility for official documents (i.e. INDs (investigational new drugs), IBs (investigator brochures), etc…)  Chair of the Groton Research Recruiting Committee for biology and chemistry.  Led effort to “reinvent” drug discovery including the identification and establishment of integrated CVMED research collaborations with academic institutions.  Co-chaired, with a commercial and development lead, a working group that produced the 10 year obesity strategy .spanning research, development and commercial.  Direct responsibility for scientific and strategic recommendations with respect to target pursuit and plans as a member of the CVMED Portfolio Team responsible for Licensing Review /Due Diligence for diabetes and obesity.  Integral member of the CVMED Leadership Team and Research Management Forum responsible for setting and leading research strategy.  Led the effort to externalize Pfizer obesity assets to venture capital, biotech and/or pharmaceutical companies.

Director 2003-2006 Obesity Biology in the Department of Cardiovascular and Metabolic and Endocrine Diseases (CVMED) at Pfizer Global Research and Development in Groton, Connecticut.  Key global representative on the Development Team that successfully moved multiple compounds to Phases 1, 2 and 3 and was responsible for up to 8 compounds at one point.  Successfully initiated and led the effort to discover and develop Pfizer‟s first novel therapeutic for the treatment of metabolic diseases.  Led and crafted the scientific rationale for several unique combination therapies that underwrote the development plans for first in human through Phase 2 studies.  Integral role in establishing a new Pfizer obesity research team in Sandwich England and establishing a global metabolic diseases portfolio.  Global research lead for a cross-Discovery, Development and Commercial team responsible for defining product concepts for obesity and obesity comorbidities.

Manager 2001-2003 Obesity Biology in the Department of Cardiovascular and Metabolic Diseases at Pfizer Global Research and Development in Groton, Connecticut  Led the nomination of multiple development compounds for obesity/diabetes including 5 in one year.  Initiated and co-chaired a combination therapy team that established a strategy and framework for making decisions on how and when to combine

2 Andrew Gordon Swick

compounds/drugs for the treatment of diabetes and obesity across research through to marketing.  Chaired a matrixed Early Clinical Development Team for obesity that moved a compound, previously discovered through the efforts of my lab, through Phase 1 clinical studies.

Project Leader 1998-2001 Diabetes and Obesity group of the Department of Cardiovascular and Metabolic Diseases at Pfizer Central Research in Groton, Connecticut.  Integral role in justifying, building and leading the formation of an independent obesity research team at Pfizer.  Reviewed and made recommendations on multiple potential licensing opportunities  Key member of early clinical development team

Senior Research Investigator 1997-1998 Diabetes and Obesity group of the Department of Cardiovascular and Metabolic Diseases at Pfizer Central Research in Groton, Connecticut.  Led 2 independent Discovery research teams  Established external collaborations to aid discovery efforts

Senior Research Scientist 1992-1997 Diabetes and Obesity group of the Department of Cardiovascular and Metabolic Diseases at Pfizer Central Research in Groton, Connecticut.  Initiated and successfully led a novel nuclear receptor program for the treatment of metabolic diseases  Developed novel in vitro and in vivo models to guide decision-making  Identified and nominated several development compounds

Postdoctoral Fellow l990-1992 In the laboratory of M. Daniel Lane, Ph.D., in the Department of Biological Chemistry at the Johns Hopkins University School of Medicine.

NIH Postdoctoral trainee 1987-1990 In the laboratory of Jane C. Azizkhan, Ph.D., at the Lineberger Cancer Research Center of the University of North Carolina at Chapel Hill.

Research and Teaching Assistant 1983-1987 Research Assistant at the University of Wisconsin at Madison under the direction of Robert W. Swick, Ph.D. (no kinship). (1984-1985) Teaching Assistant under the direction of Robert D. Steele, Ph.D.

Research Assistant 1982-1983 Vanderbilt University in the Department of under the direction of Conrad Wagner, Ph.D.

3 Andrew Gordon Swick

Research Assistant 1981-1982 University of Nebraska at Lincoln under the direction of Constance Kies, Ph.D.

Laboratory Assistant 1980-1981 University of Florida at Gainesville in the Department of Endocrinology and under the direction of Robert Misbin, M.D.

HONORS Early Clinical Management Team of the Year, Pfizer Global Research and Development 2007 da Vinci Award for Innovation, Pfizer Global Research and Development 2006 Therapeutic Strategy Award, Pfizer Global Research and Development 2004

MEMBERSHIPS 1987 Sigma Xi 1992 American Society for Biochemistry and Molecular Biology 2000 American Society for Nutritional Sciences 2008 New York Academy of Sciences Diabetes and Obesity Steering Committee 2011 UNC Nutrition and Obesity Research Center (NORC) member 2011 New York Academy of Sciences Overnutrition Steering Committee

PUBLICATIONS

Refereed Journal Articles:

1. Ralph P. Robinson , Jeremy A. Bartlett, Peter Bertinato, Andrew J. Bessire, Judith Cosgrove, Patrick M. Foley, Tara B. Manion, Martha L. Minich, Brenda Ramos, Matthew R. Reese, Theodore J. Schmahai, Andrew G. Swick , David A. Tess, Alfin Vaz, Angela Wolford. (2011) Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide. Bioorg. and Med. Chem. Let. 21:4150-4154.

2. C.M. Boustany-Kari, M.V. Jackson, C.P. Gibbons, A.G. Swick (2011) Leptin potentiates the anti-obesity effects of rimonabant. European Journal of Pharmacology, Volume 658, Issues 2-3, 11: 270-276

3. Richard L. Elliott, Kimberly O. Cameron*, Janice E. Chin, Jeremy A. Bartlett, Elena E. Beretta, Yue Chen, Paul Da Silva Jardine, Jeffrey S. Dubins, Melissa L. Gillaspy, Diane M. Hargrove, Amit S. Kalgutkar, Janet A. LaFlamme, Mary E. Lame, Kelly A. Martin, Tristan S. Maurer, Nancy A. Nardone, Robert M. Oliver, Dennis O. Scott, Dexue Sun, Andrew G. Swick, Catherine E. Trebino, Yingxin Zhang, (2010) Discovery of N-Benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1- phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N- isopropylacetamide, an Orally Active, Gut-Selective CCK1 Receptor Agonist for the Potential Treatment of Obesity. Bioorg. and Med. Chem. Let. 20:6797- 6801.

4 Andrew Gordon Swick

4. R. Wang and A.G. Swick (2009) Identification and characterization of a leptin- responsive human cell line. Biochem. Biophys. Res. Comm. 379 (4):835-839.

5. J.A Siuciak, D. Chapin, S.A. McCarthy, V. Guanowsky, J. Brown, P. Chiang, R. Marala, T. Patterson, P.A. Seymour, A.G. Swick and P. Iredale (2007) CP- 809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology, vol. 52( 2):279-90.

6. J.J. Ramsey, J.W. Kemnitz, W. Newton. K. Hagopian, T.A. Patterson and A.G. Swick (2005) Food intake in rhesus monkeys following central administration of orexins. Regulatory Peptides. 124(1-3):209-14.

7. A.M. Mistry , AG. Swick and D.R. Romsos (2004) Leptin acts peripherally to limit meal-induced increases in plasma insulin concentrations in mice: a brief communication. Experimental Biology & Medicine. 229(10):1033-7.

8. J. Lee, A.G. Swick and D.R. Romsos (2003) Leptin constrains phospholipase C-protein kinase C induced insulin secretion via a phosphatidylinositol 3-kinase- dependent pathway. Experimental Biology & Medicine. 228(2):175-82.

9. Dow R.L. Schneider S.R. Paight E.S. Hank R.F. Chiang P. Cornelius P. Lee E. Newsome W.P. Swick A.G. Spitzer J. Hargrove DM. Patterson TA. Pandit J. Chrunyk B.A. LeMotte P.K. Danley D.E. Rosner M.H. Ammirati M.J. Simons SP. Schulte G.K. Tate B.F. DaSilva Jardine P. (2003) Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRbeta subtype-selective thyromimetics. Bioorganic & Medicinal Chemistry Letters. 13(3):379-82.

10. B.P. Morgan, A.G. Swick, D.M. Hargrove, J.A. LaFlamme, M.S. Moynihan,, R.S. Carroll, K.A. Martin, E. Lee, D. Decosta, and J. Bordner (2002) Selective glucocorticoid receptor modulators: 1) development of potent, non-steroidal and highly selective glucocorticoid receptor modulators J. Med. Chem. 45(12):2417- 24.

11. J.A.Kanaley, C. Sames, L. Swisher, A.G. Swick, L.L. Ploutz-Snyder, C.M. Steppan, K.S. Sagendorf, D. Feiglin, E.B. Jaynes, R.S. Weinstock. (2001) Abdominal fat distribution, blood lipids and leptin concentrations in pre and postmenopausal women. Metabolism: Clinical & Experimental. 50(8):976-82.

12. C.M.Steppan, D.T. Crawford, K.L.Chidsey-Frink, H.Z. Ke and A.G. Swick (2000) Leptin is a potent stimulator of bone growth in ob/ob mice. Reg. Peptides 92:73-78.

13. M. Jang, A.M. Mistry, A.G. Swick and D.R. Romsos (2000) Leptin rapidly inhibits hypothalamic neuropeptide Y secretion and stimulates corticotropin- releasing hormone secretion in adrenalectomized mice. J. Nutr. 130:2813- 2820.

5 Andrew Gordon Swick

14. C.M. Steppan and A.G. Swick (1999) Leptin increases brain size in ob/ob mice. Biochem. Biophys. Res. Comm. 256:600-602.

15. A.M. Mistry, A.G. Swick and D.R. Romsos (1999) Leptin alters metabolic rate before acquisition of its anorectic effect in developing neonatal mice. Am. J. Physiol. 273:R742-747.

16. J.J. Ramsey, R.J. Colman, A.G. Swick and J.W. Kemnitz (1998) Oxygen consumption, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine. Am. J. Clin. Nutri. 68(1):42-51.

17. J.J. Ramsey, R.J. Colman, J.W. Kemnitz and A.G. Swick (1998) Different responses to leptin in rhesus monkeys: Brain transport may be limiting. J. Clin. Endo. Metab. 83(9):3230-5.

18. A.M. Mistry, A.G. Swick and D.R. Romsos (1997) Leptin rapidly lowers food intake and elevates metabolic rates in lean and ob/ob mice. J. Nutr. 127:2065- 2072.

19. J. Chen, A.G. Swick and D.R. Romsos (1997) Leptin constrains acetylcholine- induced insulin secretion from pancreatic islets of ob/ob mice. J. Clin. Invest. 100:1174-1179.

20. D.E. Jensen, A.R. Black, A.G. Swick and J.C. Azizkhan (1997) Distinct roles for Sp1 and E2F in the growth/cell cycle regulation of the DHFR promoter. J. Cell. Biochem. 67(1):24-31, 1997

21. R. W. Stevenson, R. K. McPherson, L.M. Persson, P.E. Genereux, A.G. Swick, J. Spitzer, J.J. Herbst, K.M. Andrews, D.K. Kreutter and E.M. Gibbs. (1996) The antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high fat diet. Diabetes 45:60-66.

22. S. Collins, C.M. Kuhn, Ann E. Petro, A.G. Swick, B.A. Chrunyk and R.S. Surwit (1996) Leptin stimulates sympathetic outflow to brown adipose tissue. Nature 380:677.

23. R.W. Stevenson, E.M. Gibbs, D.K. Kreutter, R.K. McPherson, D.A. Clark, B. Hulin, S.W. Goldstein, J.C. Parker, A.G. Swick, J.L. Treadway, D.M. Hargrove and G.I. Shulman (1995) The thiazolidinedione drug series. The Diabetes Annual/9, pp. 175-191.

24. A.G. Swick and M.D. Lane (1992) Identification of a transcriptional repressor down-regulated during preadipocyte differentiation. Proc. Natl. Acad. Sci. 89:1812-1816.

6 Andrew Gordon Swick

25. A.G. Swick, M. Janicot, T. Kastelic-Cheneval, J. McLenithan and M.D. Lane (1992) Promoter-cDNA directed heterologous protein expression in Xenopus laevis oocytes. Proc. Natl. Acad. Sci. 89:1812-1816.

26. H.B. Eastman*, A.G. Swick*, M.C. Schmitt and J.C. Azizkhan (1991) Stimulation of dihydrofolate reductase promoter activity by antimetabolic drugs. Proc. Natl. Acad. Sci. 88:8572-8576. (*co-first authors)

27. M.C. Blake, R. Jambou, A.G. Swick, J.W. Kahn and J.C. Azizkhan (1990) Role of GC-elements in a TATA-less housekeeping promoter. Mol. Cell. Biol. 10:6232-6241.

28. A.G. Swick, M.C. Blake, J.W. Kahn and J.C. Azizkhan (1989) Functional analysis of GC-element binding and transcription in the hamster dihydrofolate reductase gene promoter. Nuc. Ac. Res. 17(22):9291-9304.

29. A.G. Swick and R.W. Swick (1988) Changes in GDP binding to brown adipose tissue mitochondria and the uncoupling protein. Am. J. Physiol. 255:E865-870.

30. A.G. Swick, J.W. Kemnitz, W.D. Houser and R.W. Swick (1986) Norepinephrine stimulates activity of brown adipose tissue in rhesus monkeys. Int. J. Obesity 10(3):241-244.

31. A.G. Swick and R.W. Swick (1986) The enhanced thermogenic response to a diet low but adequate in protein persists in older rats and over time. Am. J. Physiol. 251(Endocrinol. Metab. 14):E438-441.

32. C.L. Gribskov, M.F. Henningfield, A.G. Swick and R.W. Swick. (1986) Evidence for unmasking of rat brown-adipose-tissue mitochondrial GDP- binding sites in response to acute cold exposure. Biochem. J. 233:743-747.

33. A.G. Swick and R.W. Swick (1986) Rapid changes in the number of GDP binding sites on brown adipose tissue mitochondria. Am. J. Physiol. 251(Endocrinol. Metab. 14):El92-195.

Manuscripts under review:

34. C. Trebino, C. Booth, A.G. Swick & V.M. Jackson, Electrical activity in ventromedial nucleus slices predicts food intake in vivo: mapping to glutamate release. (under review)

35. J.R. Hadcock, D.A. Griffith, D.O. Scott, P.A. Carpino, P. DaSilva-Jardines, R. Day, J. Dibrino, R.L. Dow, D. Dutcher, M.W. Fichtner, D. Gautreau, D. Hargrove, P.A. Iredale, D. Kelly-Sullivan, J.S. Lizano, Xingrong Liu, K. Martin, N. Nardone, R. E. O‟Connor, C.R. Rose, S. Sakya, M.A. Sands, A. G. Swick, D. Tess, J. Van Deusen, K. M. Ward, and S.C. Black Pharmacological profile

7 Andrew Gordon Swick

of CP-945,598(1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4- ethylaminopiperidine-4-carboxylic acid amide hydrochloride), a potent and selective cannabinoid CB1 receptor antagonist. (under review)

36. M.A. Hickman, T.B. Manion, R. Wang and A.G. Swick, A novel role for intestinal microsomal triglyceride transfer protein (MTP) in the control of food intake. (under review).

Invited oral presentations:

A.G. Swick, Role of the Gut in the Regulation of Body Weight (2010) seminar at the University of Georgia, Department of Foods and Nutrition, Athens, GA.

A.G.Swick, Targeting the Gut for the Treatment of Metabolic Diseases, 8th Annual International Discovery on Target – Targeting Diabetes with Novel Therapies (2009), Boston, MA

A.G. Swick, The Gut as a Target for Treating Metabolic Diseases, 5th Annual Effective and Advanced Treatments for Diabetes Conference (2009) London, England

.A.G. Swick, Keystone Symposia entitled: Molecular Control of Adipogenesis and Obesity/Neuronal Mechanisms Controlling Food Intake, Glucose Metabolism and Body Weight (2008) Banff, Canada

A.G. Swick, The Role of Intestinal Metabolism in the Regulation of Food Intake (2008) seminar at the University of Connecticut, Department of Nutritional Sciences, Storrs, CT.

A.G. Swick, Drug Discovery in Obesity and Diabetes National Atherosclerosis Forum (2008) Toronto, Ontario

A.G. Swick, Next Generation Pharmaceuticals Summit (2007) San Juan, Puerto Rico

A.G. Swick, The Link between Adiposity and Diabetes, European Center of Pharmaceutical Medicine (ECPM). ECPM is a university institute at the Medical Faculty of the University of Basel under the auspices of EUCOR, the European Confederation of the Upper Rhine Universities Basel, Freiburg i.Br. and Strasbourg. (2007) Basel, Switzerland

A.G. Swick, Regulation of Food Intake: The Gut-Brain Connection (2006), seminar at Clemson University, Department of Food and Nutrition, Clemson, South Carolina

8 Andrew Gordon Swick

A.G. Swick, Conference on Successful Disease Management Practices for Obesity and Related Disorders, (2005) London, England

A.G. Swick, Role of Glucocorticoids in the Obese Phenotype (2005) Metabolic Diseases Drug Discovery World Summit, La Jolla, CA

A.G. Swick, (2004) Time/ABC News Summit on Obesity presented by the Robert Wood Johnson Foundation Hosted by TIME and ABC News, featuring Peter Jennings (presenter and panelist)

A.G. Swick, Hormonal Regulation of Body Weight (2003) Obesity and Related Disorders Conference, London, England

A.G. Swick, The Role of Glucocorticoids in Obesity (2003) Obesity and the Metabolic Syndrome, Washington, D.C.

A.G. Swick, Glucocorticoid and Leptin Interactions (2003) Metabolic Syndrome:Novel Approaches to Target Identification and Drug Discovery, Boston, MA

A.G. Swick, Glucocorticoids, Obesity and Diabetes (2003) Diabetes Conference, London, England

A.G. Swick, Interrelationship between Glucocorticoids and Leptin. (2002) seminar at the University of Minnesota Department of Food Science and Nutrition, Minneapolis, MN.

A.G. Swick, Role of Glucocorticoids in the Control of Food Intake and Obesity Symposium on the Regulation of Food Intake, at Experimental Biology 2001, Orlando, FL.

A.G. Swick, Role of Glucocorticoids in the Obese Phenotype. (2001) seminar at the University of Arizona, Department of Nutritional Sciences, Tucson, AZ.

A.G. Swick, TNF-Induced Insulin Resistance: Effects of Thiazolidinediones (1998) American Physiological Society sponsored symposium entitled, “Pleuripotent Effects of TNF on Metabolism" at Experimental Biology „98, San Francisco, CA.

A.G. Swick, Regulation of Growth and Metabolism by Secreted from Adipocytes (1998) seminar at the University of Georgia, Department of Foods and Nutrition, Athens, GA.

A.G. Swick, The Function of Secreted Proteins from Adipose Tissue (1997) Fourth International Symposium on Obesity: Recent Advances in Understanding and Treatment, Boston, MA

9 Andrew Gordon Swick

A.G. Swick, Central and Peripheral Actions of Leptin (1996) International Congress on Anti-Obesity Drug Targets, Boston, MA

A.G. Swick Inhibition of Insulin Action by TNF- (1995) seminar at the University of Connecticut, Departemtn of Nutritional Sciences, Storrs, CT

A.G. Swick, E.M. Gibbs, D.M. Hargrove, D.K. Kreutter, J.C. Parker, J.L. Treadway and R.W. Stevenson Amelioration of Insulin Resistance by Thiazolidinedione Derivatives. (1994) Lessons from Animal Diabetes International Workshop IV, Omiya, Saitama, Japan

Patents:

Title: Glucocorticoid Receptor Modulators Inventors: R.L. Dow, K.K. Liu, B.P. Morgan and A.G. Swick Patent #: US 7166593

Title: Glucocorticoid Receptor Modulators Inventors: R.L. Dow, K.K. Liu, B.P. Morgan and A.G. Swick Patent #: US 6699893

Title: Glucocorticoid Receptor Modulators Inventors: R.L. Dow, K.K. Liu, B.P. Morgan and A.G. Swick Patent #: US 6380223

Title: Glucocorticoid Receptor Modulators Inventors: R.L. Dow, K.K. Liu, B.P. Morgan and A.G. Swick Patent #: 7713989

Title: Treatments for Obesity and Methods for Identifying Compounds Useful for Treating Obesity Inventors: J.R. Hadcock and A.G. Swick Patent #s: US 6451783

Title: Treatments for Obesity and Methods for Identifying Compounds Useful for Treating Obesity Inventors: J.R. Hadcock and A.G. Swick Patent #s: US 6734175

Title: Thyromimetic Antiobesity Agents Inventors: P. Cornelius, D.M. Hargrove, B.P. Morgan and A.G. Swick Patent #: US 6344481

Title: Thyromimetic Antiobesity Agents Inventors: P. Cornelius, D.M. Hargrove, B.P. Morgan and A.G. Swick Patent #: US 6555578

10 Andrew Gordon Swick

Title: Treatment of Skeletal Disorders Inventors: H. Ke, C.M. Steppan and A.G. Swick Patent #: US 6352970

Title: Combination Therapy for Treating Obesity or Maintaining Weight Loss Inventors: T.A. Patterson and A.G. Swick Patent Application #: 20060270655

PROFESSIONAL SERVICE 2011 NIH Integrative Physiology of Obesity and Diabetes (IPOD) Study Section Ad Hoc Reviewer 2011 Advisory Board, GTC Diabetes Summit 2011 Obesity, manuscript reviewer 2010 Advisory Board, Cambridge Healthtech Institute‟s 3rd Annual Diabetes Drug Discovery New Diabetes Drug Targets and Candidates Conference 2009 Advisory Board, Cambridge Healthtech Institute‟s 2nd Annual Diabetes Drug Discovery New Diabetes Drug Targets and Candidates Conference 2009 Chair of the Groton Research Recruiting Committee for Biology and Chemistry 2009 Advisory Board, International Quality and Productivity Center‟s Metabolic Diseases Drug Discovery & Development Conference, San Francisco, CA 2007-2009 Academic Out-posting/Collaborative Initiative for Metabolic Diseases 2007-2009 Clinical Management Team for Obesity 2008 International Union of Basic and Clinical Pharmacology - Integrative and Organ Systems Pharmacology committee 2007-2008 American Society of Pharmacology and Experimental Therapeutics Education Working Group 2004-2009 Disease Area Working Group for Obesity 2003 NIH Clinical Nutrition Research Unit Ad Hoc Grant Reviewer 2000-2009 Cardiovascular, Metabolic and Endocrine Diseases Leadership Team 2000-2009 Discovery Research Forum 2000-2009 Licensing Review /Due Diligence Team for Obesity and Diabetes 2004-2007 Chair of the Early Clinical Management Team for Obesity 2001 Chair of the Molecular Sciences Post-Doctoral Review Committee 2000 Molecular Sciences Post-Doctoral Review Committee 1998-2000 Research Building 200 Design Committee

11